在Regeneron合作伙伴Dupixent的推动下，赛诺菲走高第三季度

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, which is marketed in collaboration with Regeneron (NASDAQ:REGN).

The Paris-based firm posted €12.4B ($14.4B) in sales and €2.91 ($3.38) of business earnings per share for the third quarter, exceeding the €12.3B and €2.70 projected by analysts, The Wall Street Journal reported, citing data provided by Vara Research.

While the company’s vaccine sales fell ~8% YoY to €3.4B amid lower flu vaccine sales due mainly to higher price competition and lower vaccination rates, Dupixent sales reached €4.2B with ~26% YoY growth.

“Dupixent grew by 26.2% and exceeded for the first time both four billion euros in quarterly global sales and three billion euros in the US, despite an unfavorable currency impact,” CEO Paul Hudson remarked.

Sanofi (NASDAQ:SNY) continued to indicate a high single-digit growth in sales and a low double-digit percentage growth in business EPS for 2025 in terms of constant exchange rates.

Regarding U.S. efforts to lower drug prices in line with President Donald Trump’s Most Favored Nation policy, Sanofi (NASDAQ:SNY) CFO Francois-Xavier Roger said that talks are underway with the administration and policymakers to improve affordability and access to its products in the U.S.

"Sanofi is in constant discussion with the administration and policymakers," he said, adding that the company would "review the opportunity" to expand an initiative to provide pharmaceutical products directly to consumers.

In September, Sanofi (SNY) expanded its Insulins Valyou Savings Program to allow anyone with a valid prescription in the U.S. to purchase its insulin medications for $35 a month, regardless of their insurance status.